CO2023014181A2 - Composiciones de anticuerpos anti-tslp y usos de las mismas - Google Patents
Composiciones de anticuerpos anti-tslp y usos de las mismasInfo
- Publication number
- CO2023014181A2 CO2023014181A2 CONC2023/0014181A CO2023014181A CO2023014181A2 CO 2023014181 A2 CO2023014181 A2 CO 2023014181A2 CO 2023014181 A CO2023014181 A CO 2023014181A CO 2023014181 A2 CO2023014181 A2 CO 2023014181A2
- Authority
- CO
- Colombia
- Prior art keywords
- compositions
- tslp antibodies
- tslp
- antibody
- antibodies
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 2
- 229950008998 tezepelumab Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
- C07K16/065—Purification, fragmentation
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Pulmonology (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
La presente solicitud se refiere, en general, a composiciones que comprenden el anticuerpo anti-TSLP tezepelumab y derivados del mismo que tienen atributos de calidad del anticuerpo.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163178938P | 2021-04-23 | 2021-04-23 | |
| PCT/US2022/025994 WO2022226339A1 (en) | 2021-04-23 | 2022-04-22 | Anti-tslp antibody compositions and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2023014181A2 true CO2023014181A2 (es) | 2023-10-30 |
Family
ID=81597810
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2023/0014181A CO2023014181A2 (es) | 2021-04-23 | 2023-10-24 | Composiciones de anticuerpos anti-tslp y usos de las mismas |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20240190951A1 (es) |
| EP (1) | EP4326766A1 (es) |
| JP (1) | JP2024517418A (es) |
| KR (1) | KR20240000537A (es) |
| CN (1) | CN117203233A (es) |
| AR (1) | AR125408A1 (es) |
| AU (1) | AU2022262421A1 (es) |
| BR (1) | BR112023021867A2 (es) |
| CA (1) | CA3216655A1 (es) |
| CL (1) | CL2023003155A1 (es) |
| CO (1) | CO2023014181A2 (es) |
| CR (1) | CR20230531A (es) |
| IL (1) | IL307540A (es) |
| MX (1) | MX2023012363A (es) |
| PE (1) | PE20240068A1 (es) |
| TW (1) | TW202308690A (es) |
| UY (1) | UY39736A (es) |
| WO (1) | WO2022226339A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12110324B2 (en) | 2022-07-22 | 2024-10-08 | Flagship Pioneering Innovations Vi, Llc | Antigen binding molecules targeting thymic stromal lymphopoietin (TSLP) |
| WO2024163978A2 (en) | 2023-02-02 | 2024-08-08 | Medimmune, Llc | Treatment of chronic rhinosinusitis with anti-tslp antibody |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
| US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
| GB8516415D0 (en) | 1985-06-28 | 1985-07-31 | Celltech Ltd | Culture of animal cells |
| US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
| WO1990003430A1 (en) | 1988-09-23 | 1990-04-05 | Cetus Corporation | Cell culture medium for enhanced cell growth, culture longevity and product expression |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| DE69127627T2 (de) | 1990-08-29 | 1998-02-19 | Genpharm Int | Produktion und Nützung nicht-menschliche transgentiere zur Produktion heterologe Antikörper |
| US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
| US7982016B2 (en) | 2007-09-10 | 2011-07-19 | Amgen Inc. | Antigen binding proteins capable of binding thymic stromal lymphopoietin |
| US8359965B2 (en) | 2007-09-17 | 2013-01-29 | Oxford J Craig | Apparatus and method for broad spectrum radiation attenuation |
| TW201201840A (en) | 2010-07-15 | 2012-01-16 | Hoffmann La Roche | Antibodies specifically binding to human TSLPR and methods of use |
| AT510032B1 (de) | 2010-11-30 | 2012-01-15 | Steiner Erwin Ing | Montageeinrichtung für fassadenelemente |
| US9100245B1 (en) | 2012-02-08 | 2015-08-04 | Amazon Technologies, Inc. | Identifying protected media files |
| US20140227250A1 (en) * | 2012-08-23 | 2014-08-14 | Merck Sharp & Dohme Corp. | Stable formulations of antibodies to tslp |
| US9306926B2 (en) | 2013-03-15 | 2016-04-05 | Brian A. Truong | User authentication using unique hidden identifiers |
| CN106170554B (zh) | 2014-01-29 | 2021-08-17 | 美国安进公司 | 过表达n-糖基化途径调节基因以调节重组蛋白的糖基化 |
| JP2018509153A (ja) * | 2015-03-11 | 2018-04-05 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | Ｔｓｌｐ結合タンパク質 |
| JOP20190243A1 (ar) | 2017-04-12 | 2019-10-13 | Medimmune Llc | علاج الربو بجسم مضاد لـ tslp |
| CN110709121B (zh) | 2017-06-08 | 2022-06-24 | 安进公司 | 扭矩驱动式药物递送装置 |
| MA49757A (fr) * | 2017-08-01 | 2020-06-10 | Amgen Inc | Systèmes et procédés de préparation en temps réel d'un échantillon de polypeptide pour analyse par spectrométrie de masse |
| JP7247174B2 (ja) | 2017-11-10 | 2023-03-28 | アムジエン・インコーポレーテツド | 薬物送達デバイスのプランジャ |
| US20210041453A1 (en) | 2018-03-13 | 2021-02-11 | Amgen Inc. | Methods for the preparation of trypsin-resistant polypeptides for mass spectrometric analysis |
| WO2020081479A1 (en) | 2018-10-15 | 2020-04-23 | Amgen Inc. | Drug delivery device having damping mechanism |
| EP3866889A1 (en) | 2018-10-15 | 2021-08-25 | Amgen Inc. | Platform assembly process for drug delivery device |
| WO2020223422A1 (en) | 2019-04-30 | 2020-11-05 | Amgen Inc. | Data-driven predictive modeling for cell line selection in biopharmaceutical production |
| MA56121A (fr) | 2019-06-05 | 2022-04-13 | Amgen Inc | Procédés d'identification d'attributs de protéines thérapeutiques |
-
2022
- 2022-04-22 CN CN202280029246.4A patent/CN117203233A/zh active Pending
- 2022-04-22 IL IL307540A patent/IL307540A/en unknown
- 2022-04-22 AR ARP220101047A patent/AR125408A1/es unknown
- 2022-04-22 EP EP22722640.4A patent/EP4326766A1/en active Pending
- 2022-04-22 KR KR1020237039567A patent/KR20240000537A/ko unknown
- 2022-04-22 BR BR112023021867A patent/BR112023021867A2/pt unknown
- 2022-04-22 MX MX2023012363A patent/MX2023012363A/es unknown
- 2022-04-22 CR CR20230531A patent/CR20230531A/es unknown
- 2022-04-22 WO PCT/US2022/025994 patent/WO2022226339A1/en active Application Filing
- 2022-04-22 TW TW111115482A patent/TW202308690A/zh unknown
- 2022-04-22 JP JP2023564144A patent/JP2024517418A/ja active Pending
- 2022-04-22 AU AU2022262421A patent/AU2022262421A1/en active Pending
- 2022-04-22 US US18/287,593 patent/US20240190951A1/en active Pending
- 2022-04-22 CA CA3216655A patent/CA3216655A1/en active Pending
- 2022-04-22 PE PE2023002912A patent/PE20240068A1/es unknown
- 2022-04-27 UY UY0001039736A patent/UY39736A/es unknown
-
2023
- 2023-10-23 CL CL2023003155A patent/CL2023003155A1/es unknown
- 2023-10-24 CO CONC2023/0014181A patent/CO2023014181A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112023021867A2 (pt) | 2023-12-19 |
| CA3216655A1 (en) | 2022-10-27 |
| CL2023003155A1 (es) | 2024-04-19 |
| UY39736A (es) | 2022-10-31 |
| JP2024517418A (ja) | 2024-04-22 |
| CR20230531A (es) | 2024-01-08 |
| US20240190951A1 (en) | 2024-06-13 |
| TW202308690A (zh) | 2023-03-01 |
| EP4326766A1 (en) | 2024-02-28 |
| CN117203233A (zh) | 2023-12-08 |
| AR125408A1 (es) | 2023-07-12 |
| WO2022226339A1 (en) | 2022-10-27 |
| PE20240068A1 (es) | 2024-01-11 |
| IL307540A (en) | 2023-12-01 |
| AU2022262421A1 (en) | 2023-10-19 |
| MX2023012363A (es) | 2023-11-01 |
| KR20240000537A (ko) | 2024-01-02 |
| WO2022226339A9 (en) | 2023-08-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2023014181A2 (es) | Composiciones de anticuerpos anti-tslp y usos de las mismas | |
| CO2018008754A2 (es) | Composición farmacéutica que comprende constructos de anticuerpo biespecíficos | |
| CL2020000632A1 (es) | Composición y método para el tratamiento del autismo. | |
| UY36897A (es) | Composiciones inoculantes estables y métodos para su producción | |
| EA202092202A1 (ru) | Конструкции антител к ror | |
| CO6541621A2 (es) | Anticuerpos que se unen preferencialmente al dominio 4 extracelular de csf 1r humano y uso de los mismos | |
| CR20170425A (es) | Nuevas proteínas específicas para pioverdina y pioquelina | |
| CO2023006684A2 (es) | Anticuerpos contra sars-cov-2 y usos de los mismos | |
| DOP2022000229A (es) | Anticuerpos de cadena pesada multiespecíficos con regiones constantes de cadena pesada modificadas | |
| CL2023003124A1 (es) | Anticuerpos anti-tslp modificados | |
| MX2020003803A (es) | Composicion de proteinas de guisante que tiene calidad nutricional mejorada. | |
| ECSP23025065A (es) | Anticuerpos de cadena pesada multiespecíficos con regiones constantes de cadena pesada modificadas | |
| BR112021024956A2 (pt) | Anticorpos multiespecíficos de cadeia pesada que se ligam a cd22 e cd3 | |
| BR112021019903A2 (pt) | Composição farmacêutica aquosa, uso da composição farmacêutica aquosa e método de produção de uma composição farmacêutica aquosa | |
| CO2020008514A2 (es) | Nuevas antranilamidas, su uso como insecticida y procesos para su preparación | |
| CL2023001220A1 (es) | Inhibidores de interleucina-17 | |
| CL2023003073A1 (es) | Anticuerpos anti-cd20 y estructuras car-t | |
| BR112022027101A2 (pt) | Anticorpos multiespecíficos que se ligam a bcma | |
| MX2020004675A (es) | Formulaciones de alcohol de seda. | |
| CO2024000763A2 (es) | Composiciones y métodos de los anticuerpos anti-pacap | |
| PL428045A1 (pl) | Szczepionka do profilaktyki i leczenia zakażeń C. difficile oraz jej zastosowanie | |
| AR121242A1 (es) | Supresión de la respuesta de escape a la sombra en plantas | |
| CO2021012209A2 (es) | Composición para cuidado oral | |
| BR112019000240A2 (pt) | composições farmacêuticas | |
| PL422316A1 (pl) | Sposób otrzymywania przeciwciała monoklonalnego, przeciwciało monoklonalne, komórka CHO DG44, która koekspresjonuje przeciwciało monoklonalne oraz kompozycja je zawierająca |